Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

11.8%

2 terminated/withdrawn out of 17 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

10 recruiting

Enrollment Performance

Analytics

Phase 1

14(82.4%)

N/A

2(11.8%)

Early Phase 1

1(5.9%)

17Total

Phase 1(14)

N/A(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (17)

Showing 17 of 17 trials

NCT07500805Phase 1Not Yet Recruiting

UCL70805F in Patients With CD70-positive Advanced Renal Clear Cell Carcinoma

Role: lead

NCT06658951Not ApplicableRecruiting

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

Role: lead

NCT07010523Not ApplicableRecruiting

Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

Role: collaborator

NCT06937567Early Phase 1Recruiting

CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors

Role: collaborator

NCT06256055Phase 1Recruiting

Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

Role: lead

NCT06501183Phase 1Recruiting

Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors

Role: collaborator

NCT05693844Phase 1Recruiting

Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors

Role: collaborator

NCT05990621Phase 1Recruiting

Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic Neoplasms

Role: collaborator

NCT05947487Phase 1Recruiting

CD70 Targeted CAR-T Cells in CD70 Positive Advanced/Metastatic Solid Tumors

Role: collaborator

NCT05948033Phase 1Recruiting

CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma

Role: collaborator

NCT05848999Phase 1Unknown

UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

Role: collaborator

NCT05783089Phase 1Not Yet Recruiting

MSLN-targeted CAR-T Cells in Solid Tumors.

Role: collaborator

NCT05775666Phase 1Unknown

UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

Role: collaborator

NCT05513612Phase 1Withdrawn

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Role: collaborator

NCT05531708Phase 1Withdrawn

Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Role: collaborator

NCT05528887Phase 1Recruiting

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Role: collaborator

NCT04981691Phase 1Unknown

Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors

Role: collaborator

All 17 trials loaded